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Identity 
Other names: ACTININ-4, FSGS, FSGS1 
HGNC (Hugo): ACTN4 
Location: 19q13.2 
Local order: EIF3K, ACTN4, CAPN12. 
Note 
ACTN4 is positioned between EIF3K and CAPN12. 
Human CAPN12 and ACTN4 share 339 bases of non-
coding DNA sequence at their 3' ends (NC_000019.9, 
green box in the diagram). In mouse genome the two 
genes overlap in a similar manner (Dear et al., 2000). 
DNA/RNA 
Description 
The genomic DNA of ACTN4 (NC_000019.9) spans 
82905 base pairs between coordinates 39138267 and 
39221171 on chromosome 19, GRCh37.p10 Primary 
Assembly. ACTN4 contains 21 exons 
ACTN4 single nucleotide variants and 
insertions/deletions included in dbSNP137 (NCBI)  
count 1776 entities. 
Transcription 
The mRNA of ACTN4 (NM_004924.4) comprises 
3966 bases and bases 120-2855 form the coding 
sequence. Honda et al. (2004) described alternatively 
spliced variant originally identified in small cell lung 
cancer that is also detectable in normal brain and testis 
tissues.  
In the variant, the same length alternative sequence 
originating from the intron 8 replaces usual exon 8. 
Alternatively spliced α-actinin 4 has substitutions in the 
following aa: N248G, A250L, S262C and higher 
affinity to filamentous actin in in vitro co-
sedimentation assay. Alternative splicing of exon 19 
alters calcium sensitivity of α-actinin 4 and has been 
detected in mouse brain but not in other of the 
investigated mouse tissue samples (Lek et al., 2010; 
Foley and Young, 2013). 
Yeast two-hybrid screen of human cDNA library 
captured another splice variant lacking nt 263-1433 of 
the full-length mRNA thus removing part of the first 
and second calponin-homology domain, the first and 
partially second spectrin-like repeat from α-actinin 4 
(Chakraborty et al., 2006). 
 
Scheme of ACTN4 genomic locus. The fragment of chromosome 19q13.2 (19:39109722-39235114, GRCh37.p10 Primary Assembly) 
containing ACTN4 and surrounding DNA sequence was shown. Genes are drawn as arrows with the length approximately corresponding 
to the number of bases in each gene. Arrowheads point at the direction of transcription (5' to 3' end). 
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Organization and domain structure of α-actinin 4 molecule. Functional protein is antiparallel homodimer (upper panel). Lower panel: 
domains of the protein ordered from N to C-terminus. Abbreviations: CH - calponin-homology domain (CH1, aa 50-154 and CH2, aa 163-
269); S - spectrin-like repeats (S1, aa 293-403, S2, aa 413-518, S3, aa 528-639, and S4, aa 649-752); EF - EF-hand motifs (EF1, aa 
765-800 and EF2, aa 806-841). Amino acid positions in the α-actinin 4 are indicated according to UniprotKB/Swiss-Prot database. 
 
Pseudogene 
There are 2 known pseudogenes for ACTN4: 
ACTN4P1 (NG_022074.1) is located on chromosome 




α-Actinins are members of the spectrin superfamily 
proteins. There are four isoforms, product of different 
genes.  
Isoform 2 and 3 ("muscle" α-actinin) are constituents of 
sarcomeres in the heart and skeletal muscle. Isoform 1 
and 4 are "non-muscle" α-actinins found practically in 
every tissue. 
α-Actinin 4 is a ~100 kDa protein. It has high degree of 
similarity to α-actinin 1 isoforms: 87% identical to 
isoform b (NP_001093.1) and 85% to isoform a 
(NP_001123476.1). α-Actinin 4 is cloned and 
characterized by Honda et al. (1998) in cancer cells 
although earlier description of two non-muscle α-
actinins in chick lung exists (Imamura and Masaki, 
1992).  
All spectrin-related proteins share similar structure: N-
terminal actin-binding site formed by a pair of 
calponin-homology domains, central rod domain 
containing variable number spectrin-like repeats and C-
terminal calmodulin domain with two EF-hand motifs 
(Broderick and Winder, 2002).  
Human α-actinin harbors 4 spectrin repeats and 
functions as antiparallel homodimer so that N-terminal 
lateral domains effectively bundle the actin filaments.  
Surprisingly, very recent study has discovered α-actinin 
1/α-actinin 4 heterodimers in several cancer cell lines 
(Foley and Young, 2013). 
Expression 
α-Actinin 4 is ubiquitously expressed in normal non-
muscle cells and neoplastic tissue although the degree 
varies. 
Localisation 
α-Actinin 4 predominantly localizes in the cytoplasmic 
regions, and in some cells it can be found likewise in 
the nucleus.  
Activation of intracellular biochemical pathways or 
actin depolimerization may force the protein to 
translocate to the nucleus. α-Actinin 4 commutes 
between cytosol and nucleus through the nuclear pore
complexes as a result of hydrophobic interaction 
between the rod domain and proteins of the pores; 
nuclear localization is also cell cycle dependent 
(Kumeta et al., 2010).  
Subcellular distribution of α-actinin 4 has been 
contrasted to that of α-actinin 1 isoform in endometrial 
fibroblasts (Honda et al., 1998). α-Actinin 1 has been 
found at the ends of actin stress fibers and adherens 
junctions i.e. cell membrane associated; on the othr 
hand α-actinin 4 colocalized with the F-actin and was 
allocated in the cytosol and nucleus. However, there are 
reports showing involvement of α-actinin 4 in the 
structure of tight junctions (TJs) (Nakatsuji et al., 
2008). 
Another characteristic residence of α-actinin 4 is 
peripheral and dorsal cell protrusions associated with
cell movement (Araki et al., 2000).  
In the kidney α-actinin 4 is highly expressed and 
located in the foot processes of glomerular podocytes 
where it is essential for the kidney barrier function. 
Function 
ACTN4 product is a versatile protein. Structure of the
molecule, particularly the central spectrin repeats  
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(Djinovic-Carugo et al., 2002), allows the rod domain 
to serve as a docking site of wide variety of cytosolic 
and nuclear proteins. This fact defines participation of 
α-actinin 4 in multiple cellular processes. Majority of 
the known functional interactions at present are listed 
below: 
i/ Cytoskeletal organization and cell motility. Ability 
of α-actinin 4 to crosslink actin stress fibers and 
binding of transmembrane proteins in the cell junctions 
contributes to the maintenance of cell shape and 
anchoring to the adjacent extracellular matrix. α-
Actinin 4 is involved in targeting JRAB/MICAL-L2 
complex (important for recycling of occludin) to 
plasma membrane of TJs and participates in TJ 
formation (Nakatsuji et al., 2008). 
Together with α-actinin 1, α-actinin 4 is essential for 
the formation of dorsal stress fibers in the migrating 
cells, composition and maturation of focal adhesion. 
Tyrosine phosphorylation of α-actinins is critical in 
those processes. In the absence of α-actinins focal 
adhesions have reduced affinity to extracellular matrix 
proteins (Feng et al., 2013). 
Expression of α-actinin 4 is upregulated in the 
migrating cells and localized in their protrusions 
(Honda et al., 1998). In the stepwise process of cell 
movement it is believed that α-actinin 4 (most probably 
both non-muscle isoforms) is important for the 
detachment of rear cell end through organized 
disassembly of focal adhesions by calpain (Bhatt et al., 
2002; Shao et al., 2013). Complementary mechanism 
promoting focal adhesions disassembly is binding of 
PIP3, a lipid product of phoshoinositide 3-kinase, to the 
α-actinins CH2 domain. That interaction reduces 
affinity of α-actinins to actin and integrin (Greenwood 
et al., 2000). 
ii/ Modulation of gene transcription. It has been 
shown that α-actinin 4 interacts with nuclear receptors 
(estrogen receptor α in MCF-7 cells, vitamin D receptor 
in CV-1 cells, retinoic acid receptor and peroxisome 
proliferator-activated receptor γ in podocytes) and 
transcriptional co-activators (PCAF, SRC-1) through its 
LXXLL motif (Khurana et al., 2012a; Khurana et al., 
2012b). Binding affinity to the nuclear factors was 
stronger in the alternatively spliced (short) isoform 
identified in a human cDNA library during earlier study 
(Chakraborty et al., 2006). All the above interactions 
enhance gene transcription. In addition, α-actinin 4 
antagonizes histone deacetylase 7 thereby potentiating 
myocyte enhancer factor-2 in HeLa cells (Khurana et 
al., 2011). 
ACTN4 product also is transcriptional co-activator of 
RelA/p65 subunit of NF-kB (Aksenova et al., 2013). 
Together with nuclear factor-Y, α-actinin 4 modulates 
transcription of CYP1A1, gene involved in 
pathogenesis of certain cases of lung and breast cancer 
(Poch et al., 2004). 
α-Actinin 4 interacts with INO80 chromatin-
remodeling complex and promote Cyclin B1 
expression. In the mitotic phase, α-actinin 4 associates 
with upstream binding factor-dependent transcriptional 
complex (Kumeta et al., 2010). 
iii/ Apoptosis. Endonuclease DNaseY is involved in 
apoptotic DNA degradation. α-Actinin 4 physically 
associates with DNaseY and dramatically enhances 
activity of the enzyme and percentage of PC12 cells 
developing apoptosis induced by teniposide (Liu et al., 
2004). 
iv/ Clathrin-mediated endocytosis. α-Actinin has 
been found in isolated plasma membranes containing 
clathrin (Burridge et al., 1980) and association of α-
actinin 4 and clathrin heavy chain has been identifi d in 
prostate cancer cells. Overexpression of α-actinin 4 
facilitated transferrin endocytosis (Hara et al., 2007). 
v/ Function in glomerular podocytes. The presence of 
intact α-actinin 4 in the foot processes of podocytes is 
vital for the proper glomerular filtration. Elimination of 
the gene function in animal experiments (ACTN4 
knockout mice) and mutations in human ACTN4 result 
in the development of focal segmental 
glomerulosclerosis (Kos et al., 2003; Kaplan et al.,
2000). 
vi/ Other. Exhaustive listing of α-actinin 4 interactions 
is beyond the scope of this structured review article. 
More details can be found at least in several excellent 
review publications (Sjöblom et al., 2008; Otey and 
Carpen, 2004; Oikonomou et al., 2011). 
Homology 
In variety of species there are orthologs with high 
identity to human ACTN4 isoform: Pongo abelii 99% 
(NP_001127286.1), Bos Taurus 99% 
(NP_001091521.1), Rattus norvegicus 98% 
(NP_113863.2), Mus musculus 98% (NP_068695.1), 
Gallus gallus 92% (NP_990457.1), Xenopus laevis 
90% (NP_001087030.1), Danio rerio 86% 
(NP_955880.1). Molecular evolution of α-actinin has 
been studied (Virel and Backman, 2004). 
Mutations 
Note 
Mice deficient in ACTN4 develop progressive 
proteinuria, glomerular disease, and die in several 
months of age. Cell motility in the absence of ACTN4 
(lymphocyte chemotaxis) is increased (Kos et al., 
2003). 
Germinal 
Autosomal dominant point mutations in ACTN4 have 
been found in familial focal segmental 
glomerulosclerosis (FSGS). Kaplan et al., 2000 
identified missense substitutions K228Q, T232I, and 
S235P in 3 families affected by FSGS. 
Somatic 
Point mutation K122N has been discovered in the cell 
line derived from large cell carcinoma of the lung. The 
ACTN4-encoded protein was detected in the cDNA 
library and the ORF lacked the first 53 aa of the protein 
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(Echchakir et al., 2001). This variant was missing in the 




ACTN4 product protein is associated with disease 
progress and metastatic processes in variety of 
neoplasms due to its crucial involvement in cell 
adhesion and motility mechanisms.  
Elevated α-actinin 4 in neoplastic tissue is usually 
negative predictor of disease prognosis although there 
are reports proposing suppressive effects on tumor cells
growth and malignant phenotype. In some cancer types 
ACTN4 is candidate oncogene. 
Pancreatic cancer 
Note 
Increased level of α-actinin 4 has been determined as 
independent prognostic factor associated with most 
unfavorable prognosis in a group of 173 patients with 
invasive ductal carcinoma of the pancreas (Kikuchi et 
al., 2008). 
Amplification of chromosome 19q13.1-q13.2 has been 
reported in pancreatic cancer-derived cell lines and 
pancreatic cancer tissue.  
ACTN4 is one of the putative oncogenes in that locus 
(Miwa et al., 1996; Höglund et al., 1998). 
Breast cancer 
Note 
α-Actinin 4 is detected in many histological subtypes of 
breast cancer and subcellular localization of the 
molecule (nucleus vs. cytosol) is related to disease 
outcome.  
Cytosolic localization has been found in the types of 
cancer with more malignant histological subtype, 
metastasis, and worse survival (Honda et al., 1998). 
Proliferation of MCF-7 breast cancer cells is promoted 
by α-actinin 4 although the precise mechanism was not 
identified (Khurana et al., 2011). 
Colorectal cancer 
Note 
Specimens from 26 patients with colorectal cancer 
were immunostained to visualize the expression of α-
actinin 4. In 19 preparations (73.1%) the expression 
was increased especially in the malignant cells in the 
"focal dedifferentiation" areas. In the cell line DL 1 
(derived from colorectal adenocarcinoma) stable 
expression of ACTN4 protein dramatically changed 
cell morphology and increased motility. When those 
cells are injected into the spleens of the mice with 
severe combined immunodeficiency metastasis 
developed in the surrounding lymph nodes. On the 
other hand, injection of original DLD1 cells did not 
induce metastatic disease (Honda et al., 2005). These 
findings suggest involvement of ACTN4 in progression 
of colorectal carcinoma. 
Lung cancer 
Note 
ACTN4 gene product has been reported to exert 
multiple effects on human lung cancer cell biology and 
disease prognosis. Moreover, the available data so far 
has shown that α-actinin 4 is able to promote as well as 
suppress the malignant development reflecting 
probably the diversity of mechanisms involved in 
oncogenesis of lung cancer. Several mutations and 
splice variants in ACTN4 that influence the lung can er 
cell phenotype have been described. 
Using highly specific monoclonal antibody, 
alternatively spliced variant of ACTN4 has been 
identified exclusively in high-grade neuroendocrine 
lung tumors compared to non-neuroendocrine lung 
cancers, 96 of 176 (55%) versus 3 of 378 (0.8%) of 
investigated patients, respectively. Statistical analysis 
revealed that variant α-actinin 4 is independent 
negative prognostic factor. The protein binds F-actin 
with higher avidity (Miyanaga et al., 2013). 
Analysis of gene expression by microarray technology 
proved α-actinin 4 as a marker of worse disease 
development in non-small cell lung cancer. Higher 
expression of α-actinin 4 has been correlated to 
significantly lower survival (Yamagata et al., 2003). 
Small cell lung cancer (SCLC) cell lines and tissue 
from the patient biopsies express ACTN4 alternatively 
spliced variant, normally found in the testis. Variant α-
actinin 4 binds F-actin with higher affinity.  
This splice variant was proposed as diagnostic marker 
in SCLC (Honda et al., 2004). 
Immune response against the mutated ACTN4 in the 
patient with large cell lung cancer has been involved in 
the clinical evolution of the disease. Furthermore, after 
extraction of the primary tumor the cytotoxic T 
lymphocyte clone targeting mutated α-actinin 4 
persisted many years in the patient's blood (Echchakir 
et al., 2001). In the subsequent study, it has beenshown 
that the above point mutation removes antiproliferative 
effect of ACTN4 protein in the cancer cell line and 
supports the notion that ACTN4 may be both tumor 
suppressor as well as tumor promoter gene (Menez et 
al., 2004). 
Nervous system neoplasms 
Note 
Similar to various carcinomas, increase of ACTN4 
protein levels also appears to be involved in 
progression of certain brain tumors. In human 
astrocytoma contrasted to normal human brain tissue, 
Western blot densitometric quantification demonstrated 
~2 times higher levels of α-actinin 4 in the tumor 
samples; furthermore, in higher grades astrocytomas 
(III-IV) α-actinin 4 has additional 1.9 fold increase 
compared to low grades astrocytomas (I-II).  
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In vitro downregulation of α-actinin 4 (RNAi) in 
human astrocytoma cell lines U-373, U-87, and A172 
reduced cell adhesion and motility, cortical actin 
localization, and RhoA mRNA and protein. In U-373 
cells only α-actinin 4 promoted cell growth (Quick and 
Skalli, 2010). 
However, some experimental data support the opposite 
concept: a number of cytoskeleton-associated proteins 
show reduced expression in cancer cells and recovering 
their levels (e.g., in vitro transfection) transform the 
cells phenotype to less malignant (Glück et al., 1993). 
Human neuroblastoma cell lines with high malignant 
phenotype express lower level of α-actinin 4 compared 
to more differentiated and less malignant 
neuroblastoma cell lines. Transfection with ACTN4 has 
suppressed tumorigenicity and has converted 
neuroblasts from high to low malignant phenotype. The 
effect persisted until the level of α-actinin 4 in 
transfected cells was maintained and initial high 
malignancy phenotype recovered when α-actinin 4 
declined (Nikolopoulos et al, 2000). 
Esophageal cancer 
Note 
In a Chinese cohort of 12 patients suffering esophageal 
squamous cell carcinoma, α-actinin 4 overexpression 
has been detected in tumor tissue and proposed as a 




Involvement of α-actinin 4 in tumor pathophysiology is 
undoubtedly mediated by various mechanisms because 
of the large number of binding partner molecules that 
have been identified. In human prostate cancer cell 
lines (22RV1, PC-3, LNCaP) ACTN4 protein product 
was less abundant than in normal human prostate 
epithelial cells, an observation that is conflicting with 
the findings in the most reports investigating 
relationship ACTN4-cancer development. Increasing 
the level of α-actinin 4 in those prostate cancer cells 
markedly suppressed cell-growth (Hara et al., 2007). In 
the same report the authors propose disturbance in 
clathrin-mediated endocytosis as the main mechanism 
associated with α-actinin 4 mediated cellular effects. 
Bladder cancer 
Note 
The promoting effect of ACTN4 gene product on 
cancer invasion has also been found in the bladder 
cancer cell lines (T24, J82) and tissue from superficial 
and invasive bladder cancers. ACTN4 mRNA and 
protein levels are higher in malignant cell lines and the 
tissues from the patients versus disease-free state. 
RNAi silencing of ACTN4  
 
resulted in decreased cell invasion as measured by in 
vitro assay but did not affect the cell growth (Koizumi 
et al., 2010). 
Ovarian cancer 
Note 
Increased expression of α-actinin 4 and 19q12-13 
genetic locus amplification has been detected in 21% of 
136 cases of advanced-stage ovarian cancer. Statistical 
analysis associated higher copy number of ACTN4 as 
negative prognostic factor in the patients with ovarian 
cancer (Yamamoto et al., 2007).  
ACTN4 is a candidate oncogene in epithelial ovarian 
cancer. In subset of patients it has been found that the 
chromosome 19q12-q13 region is amplified correlating 
with higher expression of α-actinin 4 protein 
(Yamamoto et al., 2009). 
Glomerular kidney disease - Focal 
segmental glomerulosclerosis (FSGS) 
Note 
Autosomal dominant point mutations in ACTN4 are 
associated with inherited form of FSGS. Aberrant α-
actinin 4 disrupts glomerular podocytes especially their 
foot processes, which are essential in blood-urine 
barrier function.  
Clinically the disease causes proteinuria and 
deteriorating renal function.  
Mutant α-actinin 4 aggregates in the cytosol of 
podocytes and degrades faster than the normal 
molecule (Yao et al., 2004). 
Autoimmune diseases - Systemic lupus 
erythematodes (SLE) 
Note 
Autoantibodies against double stranded DNA cross-
reacting with α-actinin in the renal structures are 
associated with the development lupus nephritis 
(Mostoslavsky et al., 2001).  
Lupus-prone mouse strain overexpresses α-actinin 1 
and 4 in glomerular mesangial cells (Zhao et al., 2006). 
In patients with lupus nephritis clinical studies have 
suggested the link between anti-α-actinin 
autoantibodies and kidney involvement (Becker-Merok 
et al., 2006), however in the reports there is no 
discrimination between the 2 "non-muscle" α-actinin 
isoforms.  
Given the fact that α-actinin 4 is highly expressed in 
the affected renal structures in SLE nephritis, the
involvement of isoform 4 is probable. 
Autoimmune hepatitis type I 
Note 
Autoantibodies against α-actinin are proposed as 
markers for severity and activity of autoimmune 
hepatitis type I (Gueguen et al., 2006).  
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However, there is no report so far describing the exact 
α-actinin isoform as a target antigen. 
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